Zambiri ― Chichewa

Urticarial vasculitis ndizovuta zomwe zimazindikirika ndi ming'oma yokhalitsa kapena yobwerezabwereza. Ngakhale zizindikiro zapakhungu zimatha kukhala ngati ming'oma yosatha, ndi yapadera chifukwa ming'omayi imakhalapo kwa maora osachepera 24 ndipo imatha kuyambitsa mawanga akuda ikatha. Ngakhale nthawi zambiri sizidziwika chifukwa chake, nthawi zina zimatha kuyambitsidwa ndi mankhwala, matenda, matenda a autoimmune, matenda a myelodysplastic disorders, kapena khansa. Kafukufuku wina adalumikizanso ndi COVID-19 ndi H1N1 chimfine. Zingathenso kukhudza ziwalo zina za thupi monga minofu, impso, mapapo, mimba, ndi maso. Ngakhale kuti mtundu wina wa kuunika kwa minofu ungatsimikizire kuti munthuyo ali ndi matenda, sikofunikira nthawi zonse. Chithandizo nthawi zambiri chimayamba ndi maantibiotiki (antibiotics), dapsone, colchicine, kapena hydroxychloroquine pazovuta zazikulu.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

Mnyamata wina wazaka 35 adabwera ndi mbiri ya masiku a 15 ya zofiira (rash), zopweteka zowawa pa ntchafu ndi miyendo yonse, pamodzi ndi ululu wamagulu (joint pain). Anali ndi matenda a mkodzo kwa sabata asanatuluke zidzolo. Khungu lake linkaonetsa zikwangwani (lesions) zofiira mbali zonse za ntchafu ndi miyendo yake. Anapatsidwa oral prednisolone (40 mg/tsiku) kwa sabata limodzi ndi antihistamine yopanda tulo (fexofenadine). Pasinathe sabata, zidzolo zonse zinazimiri.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.